Shizuka Kaneko

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock, Carol Wysham, Juan P. Frías et al. · The Lancet · 2021 · 907 citations

Metabolic Syndrome, Diabetes Management, Diabetes +6

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto et al. · The Lancet Diabetes & Endocrinology · 2020 · 182 citations

Diabetes Management, Cardiovascular Disease, Medicine +8

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in <scp>J</scp> apanese people with type 2 diabetes

Yutaka Seino, Yasuo Terauchi, Takeshi Osonoi et al. · Diabetes Obesity and Metabolism · 2017 · 108 citations · Full text

Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial

Shizuka Kaneko, Francis C. C. Chow, Dong Seop Choi et al. · Diabetes Research and Clinical Practice · 2014 · 80 citations · Full text